Actuate Therapeutics Inc近日向美国食品药品监督管理局(FDA)提交了更新的临床数据包,此举旨在为公司计划在未来几个月内与FDA和欧洲药品管理局(EMA)进行的监管互动提供支持。
这一举措表明该公司正在积极推进其药物开发进程,通过向监管机构提供最新的临床试验数据,为后续的监管审查和批准流程奠定基础。
Actuate Therapeutics Inc近日向美国食品药品监督管理局(FDA)提交了更新的临床数据包,此举旨在为公司计划在未来几个月内与FDA和欧洲药品管理局(EMA)进行的监管互动提供支持。
这一举措表明该公司正在积极推进其药物开发进程,通过向监管机构提供最新的临床试验数据,为后续的监管审查和批准流程奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.